Jump to Navigation

Antidepressants > Research Update

FDA Publishes Article Critical of Vilazodone Data

It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.

FDA Warning: High Doses of Citalopram May Be Dangerous for the Heart

The editors at TCPR, as well as many of you, received a notice issued by the FDA on August 24, 2011 warning us that citalopram (Celexa) at doses higher than 40 mg may cause dangerous prolongation of the QT interval, which can increase the risk of cardiac arrhythmias (including the potentially fatal torsade de pointes).

St. John’s Wort or Celexa for Minor Depression?

Whether minor depression responds to antidepressant medication is up for debate, with few studies yielding mixed results.

Combined Antidepressants No More Effective than Monotherapy

The well known Star*D trial yielded disappointingly low remission and response rates in depressed patients who were put on citalopram (Celexa) for eight weeks. Recently, some clinicians have advocated starting depressed patients with a combination of antidepressants, in the hopes that targeting multiple neurotransmitters will boost efficacy.

Long-Term Exercise May Extend Remission in Depression

Regular exercise can extend remission from major depression, regardless of whether remission was initially achieved through exercise or medication, a new study suggests.

Antidepressant Response Not Linked to Serotonin Transporter Gene

SSRIs theoretically work by inhibiting the reuptake of serotonin, presumably by blocking the serotonin transporter pump whose job is to clean up excess serotonin in the synapses between neurons.

SNRIs Likely No Better than SSRIs for Depression

Due to their inhibition of both serotonin and norepinephrine reuptake, the SNRIs venlafaxine (Effexor) and duloxetine (Cymbalta) have been billed as possessing an advantage over SSRIs.